Secukinumab Dosage
Medically reviewed by Drugs.com. Last updated on Feb 13, 2025.
Applies to the following strengths: 150 mg/mL; 75 mg/0.5 mL; 300 mg/2 mL; 25 mg/mL
Usual Adult Dose for:
- Plaque Psoriasis
- Psoriatic Arthritis
- Ankylosing Spondylitis
- Non-Radiographic Axial Spondyloarthritis
- Hidradenitis Suppurativa
Usual Pediatric Dose for:
Additional dosage information:
Usual Adult Dose for Plaque Psoriasis
300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- For some patients: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter may be acceptable
Comments:
- Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.
Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Usual Adult Dose for Psoriatic Arthritis
IV DOSAGE:
- With a Loading Dose:
- Loading dose: 6 mg/kg IV at Week 0
- Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
- Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
- Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)
SUBCUTANEOUS DOSAGE:
For Psoriatic Arthritis Patients With Coexistent Moderate to Severe Plaque Psoriasis: 300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- For some patients: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter may be acceptable
For Other Psoriatic Arthritis Patients:
- With a loading dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Without a loading dose: 150 mg subcutaneously every 4 weeks
- If active psoriatic arthritis continues: Consider increasing the dosage to 300 mg subcutaneously every 4 weeks.
Comments:
- This drug may be administered with or without methotrexate.
- IV dosage: This drug should be administered over 30 minutes.
- Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.
Use: For the treatment of active psoriatic arthritis
Usual Adult Dose for Ankylosing Spondylitis
IV DOSAGE:
- With a Loading Dose:
- Loading dose: 6 mg/kg IV at Week 0
- Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
- Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
- Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)
SUBCUTANEOUS DOSAGE:
- With a Loading Dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Without a Loading Dose: 150 mg subcutaneously every 4 weeks
- If Active Ankylosing Spondylitis Continues: Consider increasing the dosage to 300 mg subcutaneously every 4 weeks.
Comments:
- IV dosage: This drug should be administered over 30 minutes.
- Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.
Use: For the treatment of patients with active ankylosing spondylitis
Usual Adult Dose for Non-Radiographic Axial Spondyloarthritis
IV DOSAGE:
- With a Loading Dose:
- Loading dose: 6 mg/kg IV at Week 0
- Maintenance dose: 1.75 mg/kg IV every 4 weeks thereafter
- Without a Loading Dose: 1.75 mg/kg IV every 4 weeks
- Maximum Dose: 300 mg/dose (for 1.75 mg/kg maintenance dose)
SUBCUTANEOUS DOSAGE:
- With a Loading Dose: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Without a Loading Dose: 150 mg subcutaneously every 4 weeks
Comments:
- IV dosage: This drug should be administered over 30 minutes.
- Subcutaneous dosage: Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.
Use: For the treatment of patients with active non-radiographic axial spondyloarthritis with objective signs of inflammation
Usual Adult Dose for Hidradenitis Suppurativa
300 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- If patient response is not adequate: Consider increasing the dosage to 300 mg subcutaneously every 2 weeks.
Comments:
- Each 300 mg dose is administered as 1 subcutaneous injection of 300 mg or as 2 subcutaneous injections of 150 mg.
Use: For the treatment of patients with moderate to severe hidradenitis suppurativa
Usual Pediatric Dose for Plaque Psoriasis
6 years and older:
- Weight less than 50 kg (at time of dosing): 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Weight at least 50 kg (at time of dosing): 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Use: For the treatment of moderate to severe plaque psoriasis in patients who are candidates for systemic therapy or phototherapy
Usual Pediatric Dose for Juvenile Psoriatic Arthritis
2 years and older:
- Weight 15 to less than 50 kg: 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Weight at least 50 kg: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Comments:
- This drug may be administered with or without methotrexate.
Use: For the treatment of active juvenile psoriatic arthritis
Usual Pediatric Dose for Enthesitis-Related Arthritis
4 years and older:
- Weight 15 to less than 50 kg: 75 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
- Weight at least 50 kg: 150 mg subcutaneously at Weeks 0, 1, 2, 3, and 4, and every 4 weeks thereafter
Use: For the treatment of active enthesitis-related arthritis
Renal Dose Adjustments
Data not available
Liver Dose Adjustments
Data not available
Precautions
CONTRAINDICATIONS:
- Previous serious hypersensitivity reaction to the active component or any of the ingredients
IV administration: Safety and efficacy have not been established in patients younger than 18 years.
Subcutaneous administration:
- Pediatric plaque psoriasis: Safety and efficacy have not been established in patients younger than 6 years.
- Juvenile psoriatic arthritis: Safety and efficacy have not been established in pediatric patients weighing less than 15 kg or younger than 2 years.
- Enthesitis-related arthritis: Safety and efficacy have not been established in pediatric patients weighing less than 15 kg or younger than 4 years.
- Hidradenitis suppurativa: Safety and efficacy have not been established in patients younger than 18 years.
Consult WARNINGS section for additional precautions.
Dialysis
Data not available
Other Comments
Administration advice:
- Before starting this drug, evaluate for active/latent tuberculosis (TB).
- Do not start this drug in patients with active TB infection; initiate treatment of latent TB before starting this drug.
- Before starting this drug, complete all age-appropriate vaccinations as recommended by current immunization guidelines.
- Solution in vials is for IV use in adult patients only.
- IV infusion is only for use by a health care professional in a health care setting.
- Administer IV infusion only in adults with psoriatic arthritis, ankylosing spondylitis, or non-radiographic axial spondyloarthritis.
- Use only an infusion set with an in-line, sterile, nonpyrogenic, low protein-binding filter (pore size 0.2 micrometer).
- Administer the infusion at a flow rate of about 3.3 mL/min for a 100 mL bag or 1.7 mL/min for a 50 mL bag (total administration time: 30 minutes).
- When infusion is complete, flush the line with at least 50 mL of 0.9% Sodium Chloride Injection, USP to ensure all of the drug in the line has been administered.
- Do not infuse this drug concomitantly in the same IV line with other drugs.
- UnoReady pens, Sensoready pens, and prefilled syringes are for subcutaneous use only.
- After proper training in subcutaneous injection technique:
- Adult patients may self-administer this drug or be injected by a caregiver.
- For pediatric patients, an adult caregiver should prepare and inject this drug; self-administration is not recommended.
- Administer each subcutaneous injection at a different anatomic location (e.g., upper arms, thighs, any quadrant of abdomen) than the previous injection; do not administer into areas where skin is tender, bruised, erythematous, indurated, or affected by psoriasis.
- A caregiver or health care provider may administer this drug subcutaneously in the upper, outer arm.
- Consult the Instructions for Use for more detailed instructions on the administration of this drug for patients and caregivers.
Storage requirements:
- Store refrigerated at 2C to 8C (36F to 46F); do not freeze. Keep in original carton to protect from light until time of use. Do not shake.
- IV infusion: Administer the diluted solution as soon as possible; if not administered immediately, store the diluted solution either:
- At room temperature (20C to 25C [68F to 77F]) for no more than 4.5 hours, from the start of preparation (piercing the first vial) to the completion of infusion.
- Under refrigeration (2C to 8C [36F to 46F]) for no more than 24 hours, from the start of preparation (piercing the first vial) to the completion of infusion; this time includes refrigeration of the diluted solution and the time to allow it to warm to room temperature. Protect the diluted solution from light while stored under refrigeration.
- Subcutaneous injection: If the Sensoready Pens and prefilled syringes are removed from refrigeration, they may be stored for up to 4 days at room temperature (not to exceed 30C [86F]).
- Write the date the product is removed from and returned to the refrigerator.
- Discard the product if stored outside the refrigerator more than 4 days.
- The product may be returned to the refrigerator only 1 time and must be stored at 2C to 8C (36F to 46F) until used or expired.
- Discard any unused product.
Reconstitution/preparation techniques:
- The manufacturer product information should be consulted.
- IV infusion: This drug must be diluted before administration; do not shake.
- Before dilution, allow the solution to sit for about 20 minutes at room temperature (20C to 25C [68F to 77F]).
- Use a 100 mL infusion bag for the loading dose in adult patients at any weight and for the maintenance dose in adult patients weighing more than 52 kg.
- Use a 50 mL infusion bag for the maintenance dose in adult patients weighing 52 kg or less; if a 50 mL infusion bag is not available, use a 100 mL infusion bag and withdraw and discard 50 mL of saline.
- Subcutaneous injection: The Instructions for Use should be consulted for more detailed instructions on the preparation of this drug for patients and caregivers.
- Before administration, remove this drug from the refrigerator and allow it to reach room temperature (Sensoready pen [150 mg/mL] and prefilled syringes [150 mg/mL, 75 mg/0.5 mL]: 15 to 30 minutes; UnoReady pen and prefilled syringe [300 mg/2 mL]: 30 to 45 minutes) without removing the needle cap.
IV compatibility:
- Compatible: 0.9% Sodium Chloride Injection, USP
- No physical or biochemical compatibility studies have been conducted to evaluate IV coadministration with other drugs.
General:
- This drug should be used under the guidance and supervision of a health care provider.
- Cases of anaphylaxis and angioedema have been reported during therapy.
- The removable caps of the Sensoready pen (150 mg/mL) and prefilled syringes (150 mg/mL, 75 mg/0.5 mL) contain natural rubber latex; these caps should not be handled by latex-sensitive individuals as they may cause an allergic reaction.
Monitoring:
- Gastrointestinal: For signs/symptoms of inflammatory bowel disease (during therapy)
- Infections/Infestations: For active or latent TB (before starting therapy); for signs/symptoms of active TB (during and after therapy)
Patient advice:
- Read the US FDA-approved patient labeling (Medication Guide and Instructions for Use).
- It is important to contact your physician if any symptoms of infection develop.
- Seek immediate medical attention if any symptoms of serious hypersensitivity reactions develop.
- Seek medical advice if signs/symptoms of eczema develop.
- Before potential vaccination, inform the health care practitioner that you are taking this drug.
Frequently asked questions
- Cosentyx vs Humira: How do they compare?
- Is Cosentyx a biologic / immunosuppressant?
- Does Cosentyx have a black box warning?
- What are the new drugs for plaque psoriasis?
- How long does Cosentyx take to work?
- How and where do you inject Cosentyx?
- Can I get a flu shot while taking Cosentyx?
- Does Cosentyx treat Rheumatoid Arthritis?
More about secukinumab
- Check interactions
- Compare alternatives
- Reviews (267)
- Side effects
- During pregnancy
- Drug class: interleukin inhibitors
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.